Factors affecting discontinuation of initial treatment with paroxetine in panic disorder and major depressive disorder

Código QR

Factors affecting discontinuation of initial treatment with paroxetine in panic disorder and major depressive disorder

Akiko Aoki,1 Shin Ishiguro,1 Takashi Watanabe,1 Mikito Ueda,1 Yuki Hayashi,1 Kazufumi Akiyama,2 Kazuko Kato,3 Yoshimasa Inoue,1 Shoko Tsuchimine,4 Norio Yasui-Furukori,4 Kazutaka Shimoda11Department of Psychiatry, 2Department of Biological Psychiatry and Neuroscience, Dokkyo Medical University Scho...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Aoki A, Ishiguro S, Watanabe T, Ueda M, Hayashi Y, Akiyama K, Kato K, Inoue Y, Tsuchimine S, Yasui-Furukori N, Shimoda K
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2014
Materias:	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/c746294b30fd4bf4aa93de6a2052ca31
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Efficacy of atropine combined with paroxetine in vagus nerve excitatory panic disorder
por: Du N, et al.
Publicado: (2015)

Comparative effectiveness of switching paroxetine formulation for treatment of major depressive disorder: an open-label multicenter study
por: Otsubo T, et al.
Publicado: (2018)

Effects of personality on the association between paroxetine plasma concentration and response
por: Tomita T, et al.
Publicado: (2018)

The influence of 5-HTTLPR genotype on the association between the plasma concentration and therapeutic effect of paroxetine in patients with major depressive disorder.
por: Tetsu Tomita, et al.
Publicado: (2014)

Escitalopram versus paroxetine controlled release in major depressive disorder: a randomized trial
por: Kishi T, et al.
Publicado: (2017)

Pharmacotherapy of panic disorder
por: Charles B Pull, et al.
Publicado: (2008)

Differential attentional bias in generalized anxiety disorder and panic disorder
por: Chen J, et al.
Publicado: (2013)

Sex differences in the prediction of the effectiveness of paroxetine for patients with major depressive disorder identified using a receiver operating characteristic curve analysis for early response [Corrigendum]
por: Tomita T, et al.
Publicado: (2014)

The Relationship Between Baseline Clinical Symptom Characteristics and Working Ability in Japanese Patients Treated for Major Depressive Disorder and Painful Physical Symptoms
por: Sugawara N, et al.
Publicado: (2020)

Pharmacological management of panic disorder
por: Carlo Marchesi
Publicado: (2008)

Clinical outcomes of patients with major depressive disorder treated with either duloxetine, escitalopram, fluoxetine, paroxetine, or sertraline
por: Huang J, et al.
Publicado: (2018)

Increased mean platelet volume in patients with panic disorder
por: Kokacya MH, et al.
Publicado: (2015)

The therapeutic potential of escitalopram in the treatment of panic disorder
por: Mark H Townsend, et al.
Publicado: (2007)

Duloxetine in panic disorder with somatic gastric pain
por: Preve M, et al.
Publicado: (2013)

Decreased mean platelet volume in panic disorder
por: Göğçegöz Gül I, et al.
Publicado: (2014)

Treatment discontinuation and tolerability as a function of dose and titration of duloxetine in the treatment of major depressive disorder
por: Harada E, et al.
Publicado: (2016)

Cortisol awakening response in drug-naïve panic disorder
por: Jakuszkowiak-Wojten K, et al.
Publicado: (2016)

Factors Associated with Non-Remission in Bipolar Disorder: The Multicenter Treatment Survey for Bipolar Disorder in Psychiatric Outpatient Clinics (MUSUBI)
por: Tsuboi T, et al.
Publicado: (2020)

Neural correlates of emotional processing in panic disorder
por: Mayuresh S. Korgaonkar, et al.
Publicado: (2021)

Double-blind, comparative study of milnacipran and paroxetine in Japanese patients with major depression
por: Kamijima K, et al.
Publicado: (2013)

Prevalence of Comorbid Anxiety Disorders and Their Associated Factors in Patients with Bipolar Disorder or Major Depressive Disorder
por: Inoue T, et al.
Publicado: (2020)

Double-blind, comparative study of milnacipran and paroxetine in Japanese patients with major depression [Corrigendum]
por: Kamijima K, et al.
Publicado: (2013)

Relationship Between Mood Episode and Employment Status of Outpatients with Bipolar Disorder: Retrospective Cohort Study from the Multicenter Treatment Survey for Bipolar Disorder in Psychiatric Clinics (MUSUBI) Project
por: Konno Y, et al.
Publicado: (2021)

Effect of aripiprazole on non-24-hour sleep–wake rhythm disorder comorbid with major depressive disorder: a case report
por: Matsui K, et al.
Publicado: (2017)

Anxiety sensitivity as a predictor of broad dimensions of psychopathology after cognitive behavioral therapy for panic disorder
por: Ino K, et al.
Publicado: (2017)

The differences between patients with panic disorder and healthy controls in psychophysiological stress profile
por: Kotianova A, et al.
Publicado: (2018)

Mean platelet volume and red cell distribution width levels in initial evaluation of panic disorder
por: Asoglu M, et al.
Publicado: (2016)

Prevalence of major depressive disorder among hemodialysis patients compared with healthy people in Japan using the Structured Clinical Interview for DSM-IV
por: Tomita T, et al.
Publicado: (2016)

Bipolar disorder recurrence prevention using self-monitoring daily mood charts: case reports from a 5 year period
por: Yasui-Furukori N, et al.
Publicado: (2017)

Adherence, persistence, and medication discontinuation in patients with attention-deficit/hyperactivity disorder – a systematic literature review
por: Gajria K, et al.
Publicado: (2014)

Alterations of oral microbiota in patients with panic disorder
por: Zunli Xie, et al.
Publicado: (2021)

Toward a personalized therapy for panic disorder: preliminary considerations from a work in progress
por: Caldirola D, et al.
Publicado: (2019)

Weekly and holiday-related patterns of panic attacks in panic disorder: a population-based study.
por: Li-Ting Kao, et al.
Publicado: (2014)

COMT polymorphism regulates the hippocampal subfield volumes in first-episode, drug-naive patients with major depressive disorder
por: Otsuka Y, et al.
Publicado: (2019)

A single-nucleotide polymorphism influences brain morphology in drug-naïve patients with major depressive disorder
por: Katsuki A, et al.
Publicado: (2019)

Comparative efficacy of escitalopram in the treatment of major depressive disorder
por: Mazen K Ali, et al.
Publicado: (2011)

Perceptions and impact of bipolar disorder in Japan: results of an Internet survey
por: Watanabe K, et al.
Publicado: (2016)

Elevated peripheral blood glutamate levels in major depressive disorder
por: Inoshita M, et al.
Publicado: (2018)

EEG microstate analysis in drug-naive patients with panic disorder.
por: Mitsuru Kikuchi, et al.
Publicado: (2011)

Gene expression-based biological test for major depressive disorder: an advanced study
por: Watanabe S, et al.
Publicado: (2017)